ERS clinical practice guidelines on treatment of sarcoidosis.

Baughman, Robert P; Valeyre, Dominique; Korsten, Peter; Mathioudakis, Alexander G; Wuyts, Wim A; Wells, Athol; Rottoli, Paola; Nunes, Hiliaro; Lower, Elyse E; Judson, Marc A; Israel-Biet, Dominique; Grutters, Jan C; Drent, Marjolein; Culver, Daniel A; Bonella, Francesco; Antoniou, Katerina; Martone, Filippo; Quadder, Bernd; Spitzer, Ginger; Nagavci, Blin; ... (2021). ERS clinical practice guidelines on treatment of sarcoidosis. (In Press). European respiratory journal European Respiratory Society 10.1183/13993003.04079-2020

[img] Text
Baughman_EurRespirJ_2021_AAM.pdf - Accepted Version
Restricted to registered users only until 18 June 2022.
Available under License Publisher holds Copyright.

Download (6MB) | Request a copy

BACKGROUND

The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin, or other manifestations. While glucocorticoids (GC) remain the first choice for initial treatment of symptomatic disease, prolonged use is associated with significant toxicity. GC-sparing alternatives are available. The presented treatment guideline aims to provide guidance to physicians treating the very heterogenous sarcoidosis manifestations.

MATERIALS AND METHODS

A European Respiratory Society Task Force (TF) committee composed of clinicians, methodologists, and patients with experience in sarcoidosis developed recommendations based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology. The committee developed eight PICO (Patients, Intervention, Comparison, Outcomes) questions and these were used to make specific evidence-based recommendations.

RESULTS

The TF committee delivered twelve recommendations for seven PICOs. These included treatment of pulmonary, cutaneous, cardiac, and neurologic disease as well as fatigue. One PICO question regarding small fiber neuropathy had insufficient evidence to support a recommendation. In addition to the recommendations, the committee provided information on how they use alternative treatments, when there was insufficient evidence to support a recommendation.

CONCLUSIONS

There are many treatments available to treat sarcoidosis. Given the diverse nature of the disease, treatment decisions require an assessment of organ involvement, risk for significant morbidity, and impact on QoL of the disease and treatment.

MESSAGE

An evidence based guideline for treatment of sarcoidosis is presented. The panel used the GRADE approach and specific recommendations are made. A major factor in treating patients is the risk of loss of organ function or impairment of quality of life.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)

UniBE Contributor:

Tonia, Thomai

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0903-1936

Publisher:

European Respiratory Society

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

23 Jun 2021 10:17

Last Modified:

24 Jun 2021 11:57

Publisher DOI:

10.1183/13993003.04079-2020

PubMed ID:

34140301

BORIS DOI:

10.48350/157076

URI:

https://boris.unibe.ch/id/eprint/157076

Actions (login required)

Edit item Edit item
Provide Feedback